

## **Pharmaceuticals**

#### **Driving forces**

COVID-19 has placed pharmaceutical companies in the spotlight, as companies' vaccines and treatments are at the heart of society's effort to end the pandemic. But the pharmaceutical industry has also been facing increasing scrutiny related to pricing and reimbursement of their products, as governments seek to slow the rise of health care costs, while the incremental value of innovation within traditional pharmaceuticals has declined. Companies depend heavily on human capital for innovation, continuous development of novel medicines and the quality of marketing strategies. The industry is characterized by extensive capital invested in sales and marketing and research and development, and there is a high risk of failure in product development. This makes process optimization and human capital management critical. Finally, controversies related to business ethics, competitive practices and product quality and safety have the potential to cause significant reputational and financial damage.

# Highlighted criteria & dimension weights

Environmental Dimension ... 9%

- Climate Strategy
- Operational Eco-Efficiency

Social Dimension ......41%

- Addressing Cost Burden
- Health Outcome Contribution
- Strategy to Improve Access to Drugs or Products
- Talent Attraction & Retention

- Codes of Business Conduct
- Innovation Management
- Product Quality and Recall
  Management

## Industry Awards 2022

S&P Global Gold Class	S&P Global ESG Score	
GlaxoSmithKline plc	United Kingdom	88
S&P Global Silver Class		
Roche Holding AG	Switzerland	86
Chugai Pharmaceutical Co., Ltd.	Japan	86
Sanofi	France	86
S&P Global Bronze Class		
Novartis AG	Switzerland	83
AstraZeneca PLC	United Kingdom	79
Ono Pharmaceutical Co., Ltd.	Japan	79
X	············	
Sustainability Yearbook Membe	rs	
Sustainability Yearbook Membe Daiichi Sankyo Company, Limited	rs J Japan	77
Sustainability Yearbook Membe Daiichi Sankyo Company, Limited Dr. Reddy's Laboratories Limited	rs d Japan l India	77
Sustainability Yearbook Membe Daiichi Sankyo Company, Limited Dr. Reddy's Laboratories Limited Cipla Limited*	rs J Japan	77
Sustainability Yearbook Membe Daiichi Sankyo Company, Limited Dr. Reddy's Laboratories Limited Cipla Limited* Takeda Pharmaceutical	rs d Japan India India	77 75 72
Sustainability Yearbook Membe Daiichi Sankyo Company, Limited Dr. Reddy's Laboratories Limited Cipla Limited* Takeda Pharmaceutical Company Limited	rs d Japan l India India Japan	 77 75  72
Sustainability Yearbook Membe Daiichi Sankyo Company, Limited Dr. Reddy's Laboratories Limited Cipla Limited* Takeda Pharmaceutical Company Limited Eisai Co., Ltd.	rs d Japan India India	77 75 72
Sustainability Yearbook Membe Daiichi Sankyo Company, Limited Dr. Reddy's Laboratories Limited Cipla Limited* Takeda Pharmaceutical Company Limited	rs d Japan l India India Japan	 77 75  72

<sup>\*</sup> S&P Global Industry Mover

### **Industry Statistics**

CODCIALA

Number of companies assessed	180	
Market capitalization of assessed compa	nies	
(in USD billion)	3,709.6	
Number of companies in Yearbook	14	
Market capitalization of companies in Yearbook		
(in USD billion)	1,135.6	